Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
| Author | |
|---|---|
| Abstract |
:
This study evaluated objective response and safety for the combination of granulocyte macrophage-colony stimulating factor (GM-CSF), ketoconazole, and mitoxantrone in castration-resistant prostate cancer (CRPC) patients who previously failed docetaxel-based chemotherapy. |
| Year of Publication |
:
2013
|
| Journal |
:
Cancer investigation
|
| Volume |
:
31
|
| Issue |
:
3
|
| Number of Pages |
:
177-82
|
| ISSN Number |
:
0735-7907
|
| URL |
:
http://www.tandfonline.com/doi/full/10.3109/07357907.2013.764564
|
| DOI |
:
10.3109/07357907.2013.764564
|
| Short Title |
:
Cancer Invest
|
| Download citation |
